Four of the ten (40%%) patients without muscular steatosis at baseline exhibited muscular steatosis at follow-up, while 16 of the 30 (53 %) with muscular steatosis at baseline exhibited no muscular steatosis at follow-up.
We also observed that two EWAT samples at baseline exhibited high expression of de novo lipogenesis genes, whereas the expression levels for the two other samples were much lower (data not shown).
Two of the 29 (7 %) study patients without hepatic steatosis at baseline exhibited hepatic steatosis at follow-up, while five of the 11 (45 %) with hepatic steatosis at baseline exhibited no hepatic steatosis at follow-up.
Similarly to macrovascular endothelium-independent function, RA patients with hypertension and insulin resistance at baseline exhibited greater carotid atherosclerosis at follow-up than patients without these risk factors.
Older individuals or those with less impaired IADL at baseline exhibited a slower progression rate in cognition, while younger age, living with a family member and higher cognitive status at baseline were predictors of less functional deterioration during the study.
Still, at follow-up, no individual ranked in the 1st decile at baseline exhibited a ≥ 2 decile upward shift and similarly only 1.8% of individuals ranked in the 10th decile at baseline showed a ≥ 2 decile downward shift.
In this same study, however, subjects with OA at baseline exhibited no association between obesity and a worsening of the radiographic evidence of knee OA at 30 months when not accounting for limb alignment.
Our study demonstrated that individuals with higher cognitive status at the start of ChEI therapy showed greater preserved IADL capacity over time and that those with a better IADL score at baseline exhibited a slower rate of cognitive decline.
Those with 1-h glucose ≥155 mg/dL at baseline exhibited a significantly lower β-coefficient for DI, indicating greater deterioration of β-cell function over time (model 1 [ Table 2]).
Patients who were taking higher-cost ICS drugs at baseline exhibited greater asthma severity compared with lower-cost ICS users, as indicated by several medication and diagnoses measures shown in Table 3.
